April 28, 2026 UPDATED: NorthStrive Biosciences Files New U.S. Patent Application Covering EL-22 Formulations and Dosing for Treatment of Muscle-Wasting Conditions related to GLP-1 Use, Sarcopenia, Muscle Disuse Atrophy, and Certain Neurological Disorders
April 28, 2026 Design Therapeutics Announces First Quarter 2026 Financial Results and Recent Business Updates
April 28, 2026 Galapagos’ Shareholders Adopt All Resolutions Proposed by the Board of Directors at the Annual and Extraordinary Shareholders’ Meetings 2026
April 28, 2026 WeatherPromise Named to TIME100 Most Influential Companies: Industry Leaders The list recognizes the world’s most influential brands for their impact, innovation, and achievement
